About
History
2025.02
Kick-off IND-Enabling
2023.09
In the portfolio of JLABS
2021.4
1st patent granted
2020.12
SBC003 showed neurorescuing effects in a rd10 model for RP
2019.11
SBC003 showed neuroprotective effects in an NMU model for RP
2018.11
SunRegen won the startup competition in BioEurope
2018.10
SunRegen is granted SME Seal of Excellence
2017.12
SunRegen project was one of the IMAGINE IF! Global Top 20 Finalists
2017.8
BaseLaunch, a life science accelerator in Basel Region, selects SunRegen into its portfolio
2017.5
Swiss CTI granted coaching support service to SunRegen
2017.2
SunRegen Healthcare AG was founded to develop SBC003 into a new drug
2016.12
SBC003 neuroprotective, neuro-rescuing, neurotrophic, and axon-outgrowth effects were proven by a series of in vitro Prove-of-Concept tests
2016.2
SBC003 was discovered
Team
Our core team brings extensive experience in drug research and development and medical translation, having held senior scientist and business leadership positions at world-leading multinational pharmaceutical companies such as Novartis, Roche, Merck, Alcon, and Allergan, complemented by years of international work experience. Our esteemed scientific advisory team includes heavyweights such as the former Chief Scientist of Alzheimer’s Drug R&D at Novartis Switzerland Headquarters, a former VP of Drug R&D at Novartis Switzerland Headquarters, and a former VP of Retinal Research and Development at Alcon and Allergan.
Awards
PARTNERSHIP
SunRegen Healthcare AG is Leveraging The Global Pharmaceutical Development Ecosystem And Building Partnerships With Professional CRO/CMOS Academic Institutions, And Service Organizations Related To Pharmaceutical Development
Careers
We Welcome Experienced Scientists From The CNS And Retinal Field, Or Industry Experts For Preclinical/Clinical Development To Contact Us Please Send Your CV And Cover Letter To
HR@Sunvegen Ch
